Gilbert Vera*, Chase Lisa
Lung cancer morbidity and death have remained high in recent years despite the significant improvement in lung cancer research. As a result, a more in-depth understanding of the underlying molecular mechanisms of pathogenesis and the identification of novel, highly successful therapeutic techniques of therapy are soon to come in lung cancer research. Applying an effective and trustworthy preclinical model would be one of them and would be a crucial step throughout the entire procedure. Due to the absence of a tumour microenvironment or tumour heterogeneity, traditional 2D models utilised in lung cancer research, such as lung cancer cell lines and cell-derived xenograft models, cannot accurately represent the conditions of patients. Newly created 3D in vitro constructs called organoids more accurately mimic the structure, function, and genetics of human organs. Cancer organoids, particularly those produced from specific patients, can more closely resemble actual tumour tissues and so have a higher potential for generating advances in cancer research in the future. Here, we focus mostly on recent developments in the methods and uses of lung cancer organoids, which are still in the early stages of development but have enormous potential.